{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:31:06Z","timestamp":1792751466902,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polymerization of deoxygenated hemoglobin S underlies the pathophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. Both changes have therapeutic potential for patients with SCD. Here, we evaluated the safety and tolerability of multiple ascending doses of mitapivat in adults with SCD with no recent blood transfusions or changes in hydroxyurea or l-glutamine therapy. Seventeen subjects were enrolled; 1 subject was withdrawn shortly after starting the study. Sixteen subjects completed 3 ascending dose levels of mitapivat (5, 20, and 50 mg, twice daily [BID]) for 2\u00a0weeks each; following a protocol amendment, the dose was escalated to 100 mg BID in 9 subjects. Mitapivat was well tolerated at all dose levels, with the most common treatment-emergent adverse events (AEs) being insomnia, headache, and hypertension. Six serious AEs (SAEs) included 4 vaso-occlusive crises (VOCs), non\u2013VOC-related shoulder pain, and a preexisting pulmonary embolism. Two VOCs occurred during drug taper and were possibly drug related; no other SAEs were drug related. Mean hemoglobin increase at the 50 mg BID dose level was 1.2 g\/dL, with 9 of 16 (56.3%) patients achieving a hemoglobin response of a \u22651 g\/dL increase compared with baseline. Mean reductions in hemolytic markers and dose-dependent decreases in 2,3-DPG and increases in ATP were also observed. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. This trial was registered at www.clinicaltrials.gov as #NCT04000165.<\/jats:p>","DOI":"10.1182\/blood.2022015403","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T16:03:37Z","timestamp":1652717017000},"page":"2053-2062","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":77,"title":["A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4147-8388","authenticated-orcid":false,"given":"Julia Z.","family":"Xu","sequence":"first","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Conrey","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Frey","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Gwaabe","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Menapace","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7548-0243","authenticated-orcid":false,"given":"Laxminath","family":"Tumburu","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Lundt","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Lequang","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[{"name":"2Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Glass","sequence":"additional","affiliation":[{"name":"2Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Dunkelberger","sequence":"additional","affiliation":[{"name":"2Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Iyer","sequence":"additional","affiliation":[{"name":"3Agios Pharmaceuticals, Inc., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Mangus","sequence":"additional","affiliation":[{"name":"3Agios Pharmaceuticals, Inc., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kung","sequence":"additional","affiliation":[{"name":"3Agios Pharmaceuticals, Inc., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-6109","authenticated-orcid":false,"given":"Lenny","family":"Dang","sequence":"additional","affiliation":[{"name":"3Agios Pharmaceuticals, Inc., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-0924","authenticated-orcid":false,"given":"Penelope A.","family":"Kosinski","sequence":"additional","affiliation":[{"name":"3Agios Pharmaceuticals, Inc., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hawkins","sequence":"additional","affiliation":[{"name":"3Agios Pharmaceuticals, Inc., Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Jeffries","sequence":"additional","affiliation":[{"name":"4Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9244-5407","authenticated-orcid":false,"given":"William A.","family":"Eaton","sequence":"additional","affiliation":[{"name":"2Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-6501","authenticated-orcid":false,"given":"Swee","family":"Lay Thein","sequence":"additional","affiliation":[{"name":"1Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 1","key":"2022111016254187400_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-137716","article-title":"Phase 1 multiple ascending dose study of safety, tolerability, and pharmacokinetics\/pharmacodynamics of mitapivat (AG-348) in subjects with sickle cell disease","volume":"136","author":"Xu","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2022111016254187400_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2021-145398","article-title":"Mitapivat (AG-348) demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin s polymerization kinetics in adults with sickle cell disease: a phase 1 dose escalation study","volume":"138","author":"Xu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2022111016254187400_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-genom-083117-021320","article-title":"Sickle cell anemia and its phenotypes","volume":"19","author":"Williams","year":"2018","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"6","key":"2022111016254187400_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022111016254187400_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-bioeng-070909-105339","article-title":"Sickle cell biomechanics","volume":"12","author":"Barabino","year":"2010","journal-title":"Annu Rev Biomed Eng"},{"issue":"1","key":"2022111016254187400_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"2022111016254187400_bib7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"2022111016254187400_bib8","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3324\/haematol.2019.239343","article-title":"Thromboinflammatory mechanisms in sickle cell disease: challenging the hemostatic balance","volume":"105","author":"Conran","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2022111016254187400_bib9","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1172\/JCI133639","article-title":"The multifaceted role of ischemia\/reperfusion in sickle cell anemia","volume":"130","author":"Hebbel","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2022111016254187400_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.hoc.2015.11.004","article-title":"The present and future global burden of the inherited disorders of hemoglobin","volume":"30","author":"Piel","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"Suppl 4","key":"2022111016254187400_bib11","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"14","key":"2022111016254187400_bib12","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2020001469","article-title":"Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?","volume":"4","author":"Telen","year":"2020","journal-title":"Blood Adv"},{"issue":"6483","key":"2022111016254187400_bib13","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.aba3827","article-title":"Treating sickle cell anemia","volume":"367","author":"Tisdale","year":"2020","journal-title":"Science"},{"issue":"11","key":"2022111016254187400_bib14","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41587-021-01121-0","article-title":"Sickle cell gene therapies approach watershed","volume":"39","author":"Sheridan","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2022111016254187400_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-med-120611-143127","article-title":"Sickle cell disease, vasculopathy, and therapeutics","volume":"64","author":"Kassim","year":"2013","journal-title":"Annu Rev Med"},{"issue":"20","key":"2022111016254187400_bib16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2022111016254187400_bib17","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","article-title":"Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Howard","year":"2021","journal-title":"Lancet Haematol"},{"issue":"5","key":"2022111016254187400_bib18","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/S2352-3026(21)00098-3","article-title":"Will the changing therapeutic landscape meet the needs of patients with sickle cell disease?","volume":"8","author":"Inusa","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"2022111016254187400_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.25687","article-title":"Hemoglobin S polymerization and sickle cell disease: a retrospective on the occasion of the 70th anniversary of Pauling\u2019s Science paper","volume":"95","author":"Eaton","year":"2020","journal-title":"Am J Hematol"},{"issue":"20","key":"2022111016254187400_bib20","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2022111016254187400_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/labmed\/27.5.329","article-title":"Erythrocytes metabolism and enzyme defects","volume":"27","author":"Brown","year":"1996","journal-title":"Lab Med"},{"key":"2022111016254187400_bib22","author":"Bunn","year":"1986"},{"issue":"11","key":"2022111016254187400_bib23","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood.V85.11.3289.bloodjournal85113289","article-title":"Antisickling effects of 2,3-diphosphoglycerate depletion","volume":"85","author":"Poillon","year":"1995","journal-title":"Blood"},{"issue":"5","key":"2022111016254187400_bib24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1182\/blood.V76.5.1028.1028","article-title":"2,3-Diphosphoglycerate and intracellular pH as interdependent determinants of the physiologic solubility of deoxyhemoglobin S","volume":"76","author":"Poillon","year":"1990","journal-title":"Blood"},{"issue":"3","key":"2022111016254187400_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1089\/ham.2020.0159","article-title":"Impact of pharmacologically left shifting the oxygen-hemoglobin dissociation curve on arterial blood gases and pulmonary gas exchange during maximal exercise in hypoxia","volume":"22","author":"Stewart","year":"2021","journal-title":"High Alt Med Biol"},{"issue":"36","key":"2022111016254187400_bib26","doi-asserted-by":"crossref","first-page":"15320","DOI":"10.1073\/pnas.0904614106","article-title":"ATP-dependent mechanics of red blood cells","volume":"106","author":"Betz","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2022111016254187400_bib27","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1182\/blood-2016-11-753525","article-title":"AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency","volume":"130","author":"Kung","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2022111016254187400_bib28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.604","article-title":"Phase 1 single- and multiple-ascending-dose randomized studies of the safety, pharmacokinetics, and pharmacodynamics of AG-348, a first-in-class allosteric activator of pyruvate kinase R, in healthy volunteers","volume":"8","author":"Yang","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"2022111016254187400_bib29","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1902678","article-title":"Safety and efficacy of mitapivat in pyruvate kinase deficiency","volume":"381","author":"Grace","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"49","key":"2022111016254187400_bib30","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1021\/acs.jpcb.8b07638","article-title":"Theoretical simulation of red cell sickling upon deoxygenation based on the physical chemistry of sickle hemoglobin fiber formation","volume":"122","author":"Dunkelberger","year":"2018","journal-title":"J\u00a0Phys Chem B"},{"issue":"supp 1","key":"2022111016254187400_bib31","first-page":"576","article-title":"Long-term efficacy and safety of the oral pyruvate kinase activator mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia","volume":"138","author":"Kevin","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2022111016254187400_bib32","doi-asserted-by":"crossref","first-page":"e0229959","DOI":"10.1371\/journal.pone.0229959","article-title":"Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis","volume":"15","author":"Ataga","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"2022111016254187400_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/bjh.17578","article-title":"Time to rethink haemoglobin threshold guidelines in sickle cell disease","volume":"195","author":"Ballas","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2022111016254187400_bib34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","article-title":"ICA-17043-10 Study Investigators. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)","volume":"153","author":"Ataga","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2022111016254187400_bib35","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/bjh.17345","article-title":"Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the phase III trial","volume":"192","author":"Ataga","year":"2021","journal-title":"Br J Haematol"},{"issue":"21","key":"2022111016254187400_bib36","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood.2020008635","article-title":"Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy","volume":"137","author":"Rab","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2022111016254187400_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A phase\u00a03\u00a0trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2022111016254187400_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2022111016254187400_bib39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"HOPE Trial Investigators. A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2022111016254187400_bib40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease","volume":"175","author":"Oksenberg","year":"2016","journal-title":"Br J Haematol"},{"issue":"13","key":"2022111016254187400_bib41","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood.2021012070","article-title":"Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin","volume":"138","author":"Henry","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/19\/2053\/1929410\/blood_bld-2022-015403-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/19\/2053\/1929410\/blood_bld-2022-015403-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T11:26:23Z","timestamp":1668079583000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/19\/2053\/485276\/A-phase-1-dose-escalation-study-of-the-pyruvate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":41,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015403","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}